Yahoo Finance

iOnctura to Share Preclinical Data on IOA-289 at SITC in November

GENEVA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces that it will ...
Yahoo Finance

iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer Studies

GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is ...
Business Wire

iOnctura to present at ASCO encouraging Phase Ib refractory uveal melanoma data for first semi-allosteric PI3Kδ inhibitor, IOA-244

GENEVA--(BUSINESS WIRE)--iOnctura SA, a clinical-stage oncology company targeting key resistance mechanisms in solid tumors, announced today that it will present Phase Ib data on its lead pipeline ...
Yahoo Finance

iOnctura to Share Clinical and Preclinical Data on IOA-244 and IOA-289 at ESMO-IO in December

GENEVA, Nov. 23, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces it will ...